Your browser doesn't support javascript.
loading
Efficacy of nab­paclitaxel vs. Gemcitabine in combination with S­1 for advanced pancreatic cancer: A multicenter phase II randomized trial.
Guo, Xi; Lou, Wenhui; Xu, Yaolin; Zhuang, Rongyuan; Yao, Lie; Wu, Junwei; Fu, Deliang; Zhang, Jun; Liu, Jing; Rong, Yefei; Jin, Dayong; Wu, Wenchuan; Xu, Xuefeng; Ji, Yuan; Wu, Lili; Lv, Minzhi; Yao, Xiuzhong; Liu, Xiaowei; Wang, Dansong; Kuang, Tiantao; Liu, Liang; Wang, Wenquan; Liu, Tianshu; Zhou, Yuhong.
Affiliation
  • Guo X; Department of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Lou W; Cancer Center, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Xu Y; Center of Evidence-Based Medicine, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Zhuang R; Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Yao L; Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Wu J; Department of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Fu D; Cancer Center, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Zhang J; Center of Evidence-Based Medicine, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Liu J; Department of Pancreatic Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China.
  • Rong Y; Oncology Department, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China.
  • Jin D; Department of Pancreatic Surgery, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China.
  • Wu W; Oncology Department, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China.
  • Xu X; Oncology Department, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China.
  • Ji Y; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
  • Wu L; Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Lv M; Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Yao X; Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Liu X; Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Wang D; Department of Pathology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Kuang T; Department of Radiotherapy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Liu L; Department of Biostatistics, Clinical Research Unit, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Wang W; Department of Radiology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
  • Liu T; Department of Anti-tumor Business, Shi Yao Group European Pharmaceutical Co., Ltd., Shijiazhuang, Hebei 050035, P.R. China.
  • Zhou Y; Department of General Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China.
Oncol Lett ; 27(4): 161, 2024 Apr.
Article in En | MEDLINE | ID: mdl-38449794
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncol Lett Year: 2024 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncol Lett Year: 2024 Document type: Article Country of publication: